Is Eiko Lifescience overvalued or undervalued?

As of 17 October 2025, Eiko Lifescience has moved from a fair to an expensive valuation grade. The company is currently overvalued based on its financial metrics, with a PE ratio of 38.40, an EV to EBITDA ratio of 32.90, and a PEG ratio of 0.62. These figures suggest that the stock is trading at a premium compared to its earnings growth potential.
In comparison to its peers, Eiko Lifescience's valuation appears high, particularly when contrasted with Life Insurance, which has a PE ratio of 11.49 and an EV to EBITDA of 8.94, indicating a more attractive valuation. Additionally, Bajaj Finserv, classified as expensive, has a lower PE ratio of 34.94. The recent performance of Eiko Lifescience has also been underwhelming, with a year-to-date return of -18.73%, significantly lagging behind the Sensex's gain of 7.44% during the same period.